Globalization
Taiho Pharmaceutical’s Future
Taiho Pharmaceutical has been steadily expanding its business in the global market. We will continue strengthening our global presence, aiming to appropriately deliver treatments to patients in need around the world.
Message from
EUROPE
Taiho Pharmaceutical Group's global expansion : advancing cancer care in Europe
Peter Foertig
General Manager
TAIHO ONCOLOGY EUROPE GMBH
Taiho Oncology Europe, established in 2021, is dedicated to delivering innovative cancer treatments across Europe. As part of the Taiho Pharmaceutical group, we are building a strong medical and sales organization and are now marketing futibatinib ourselves in several European countries. Backed by state-of-the-art research labs in Japan and Switzerland, we continue to expand our oncology portfolio, ensuring the proper use of our therapies. Through global collaboration and cutting-edge science, we remain committed to shaping the future of cancer care—bringing hope, health, and smiles to patients, their families, and caregivers worldwide. As we look to the future. The team is focused on continued growth, additional product commercialization and further strengthening its reputation as a trusted partner within the scientific community.
Message from
ASIA
Aiming to deliver innovative new drugs to as many people in Asia and Oceania as possible
Yoshimasa Nishimura
Managing Director
TAIHO PHARMA ASIA PACIFIC PTE. LTD.
We uphold the shared slogan, “By Local. For Local” while also playing a key role in Taiho Pharmaceutical’s global initiatives.
Our primary mission is to provide the innovative new drugs and unique consumer healthcare products developed by Taiho Pharmaceutical to medical professionals, to patients, and consumers across countries and regions in Asia and Oceania, through the caring hands of our local employees.
Our entire team is united to give our best effort every day to bring smiles to the faces of as many locals as possible.
Message from
NORTH AMERICA
Expanding our impact in oncology worldwide
Peter Melnyk
President & CEO
TAIHO ONCOLOGY, INC.
At Taiho Oncology, our mission is to improve the lives of patients with cancer, their families and their caregivers by developing and commercializing novel treatments for solid tumors and hematological malignancies.
Since our founding in 2002, we’ve built a strong foundation of success across multiple disease states and global markets. We have an unwavering commitment to advancing innovative therapies that improve clinical outcomes and enhance quality of life – guided by science, shaped by real-world evidence and driven by what matters most to patients.
Taiho Oncology, Inc. is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is a part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey, United States and overseas Taiho Pharmaceutical’s European and Canadian operations, which are in Baar, Switzerland and Oakville, Ontario, Canada.